
Overview
Background
Professor David Johnson PSM
MB BS (Hons, Univ Medal), PhD (Syd), DMed(Res), FASN, FISN, FAHMS, FRACP
Department of Kidney and Transplant Services, Division of Medicine, Building 31, Princess Alexandra Hospital
david.johnson2@health.qld.gov.au
David Johnson is full-time Director of the Metro South Kidney and Transplant Service (MSKATS) and Medical Director of the Queensland Kidney Transplant Service (QKTS) at Princess Alexandra Hospital, Professor of Medicine and Professor of Population Health at University of Queensland, and Director of the Centre for Kidney Disease Research in Brisbane, Australia. He has a number of international leadership responsibilities, including Co-Chair of the International Society of Nephrology Global Kidney Health Atlas (ISN GKHA), Co-Chair of the International Society for Peritoneal Dialysis (ISPD) Guidelines on Peritonitis Prevention and Treatment, Co-Chair of the Global PDOPPS Steering Committee, Chair of SONG-PD, Immediate Past President of the Australian and New Zealand Society of Nephrology (ANZSN), Past President of the ISPD (2018-2020), Past Councillor of the ISN (2013-2019), and member of the ISN-ACT, ISN Research and ISN Monitor groups. He is currently a chair or member of 11 national and 7 international guideline groups and is ranked by Expertscape as the “top-rated expert in dialysis in the world during the years 2013-2023.” He has influenced policy and practice through his leadership as Deputy Chair of the Australian Better Evidence And Translation in Chronic Kidney Disease (BEAT-CKD) program, Deputy Chair of the Australasian Kidney Trials Network (AKTN), Chair of the Primary Healthcare Education Advisory Committee to Kidney Health Australia (PEAK), Co-Chair of the Australasian Creatinine and eGFR Consensus Working Party, Co-Chair of the Australasian Proteinuria Consensus Working Party, Member and Past-Chair of the ANZDATA Registry Peritoneal Dialysis Working Group, and Past-Chair of the Queensland Statewide Renal Clinical Network.
Having published over 1200 original manuscripts in peer-reviewed journals and presented over 550 abstracts at national and international scientific meetings, he brings critical expertise in designing and conducting multi-centre, multi-national randomised controlled trials (RCTs), developing national and international registries, using innovative research methodologies (such as registry-based RCTs) and implementing trial findings into practice. He has held lead roles in high-impact, large, multi-centre RCTs that have informed global clinical practice, including CKD-FIX, IDEAL, balANZ, HONEYPOT, TESTING, HERO, and IMPENDIA. He is currently principal investigator of the TEACH-PD and INCH-HD trials, and chair of the PHOSPHATE Trial Global Steering Committee. He helped establish the Australian Peritonitis Registry and led the highly successful National PD Peritonitis Quality Improvement Project, which reduced national peritonitis rates by two-thirds. He also led the universal implementation of automated laboratory reporting of eGFR in ANZ which increased national detection rates by 40%.
He has won numerous awards for both his basic science and clinical research science studies, including the ANZSN TJ Neale Award for “outstanding contributions to nephrologic science” (2005), the US National Kidney Foundation International Distinguished Medal (2014), the Canadian Society of Nephrology Dimitrios Oreopoulos Award (2017) and the Asia-Pacific Society of Nephrology Priscilla Kincaid-Smith Award (2021). He was a Queensland finalist in the Australian of the Year Awards in 2009 and was awarded a Public Service Medal by the Governor-General of Australia in 2011 for outstanding public service, particularly research into the early detection and management of kidney disease.
Availability
- Professor David Johnson is:
- Available for supervision
Fields of research
Qualifications
- Doctoral Diploma, The University of Queensland
Research interests
-
Chronic kidney disease
-
Peritoneal dialysis
-
Haemodialysis
-
Kidney transplantation
Research impacts
Chronic kidney disease (CKD) is increasingly recognised as a major public health problem in Australia and worldwide. The Centre for Kidney Disease Research (CKDR) is one of Australia’s leading kidney disease research centres with an international reputation for excellence in research. The researchers of the CKDR are working at the forefront of global trends in research to understand the cellular and molecular basis of kidney disease and to trial innovative new clinical treatments to improve the health and well-being of people with kidney disease. Renowned for its studies in acute and chronic kidney disease and kidney cancers, the CKDR has particular expertise in translating results from laboratory and clinical sciences for application to improve public health outcomes.
The vision of our research program is to increase global equity in access to affordable, sustainable, quality kidney care. Some of the major achivements of the research program to date have been determining the ideal time to commence dialysis, the role of statins in improving cardiovascular outcomes in patients with kidney disease, biocompatible peritoneal dialysis fluid use, glucose-sparing peritoneal dialysis prescriptions for people with diabetes and kidney failure, mupirocin versus honey prophylaxis in peritoneal dialysis, anaemia treatment in chronic kidney disease, the role of allopurinol in preventing CKD progression, and the role of oral steroids in IgA nephropathy. A significant dataset has also been generated from the largest health survey conducted in the world (Global Kidney Health Atlas 2017, 2019, 2023). It is available to researchers globally, has informed WHO policy, underpinned advocacy activities to put kidney health on the international agenda; allowed benchmarking of progress for individual countries; enabled longitudinal evaluation of the organisation and structure of kidney care globally to inform policy, and has been used to facilitate policy changes and care strategies in international jurisdictions (Mexico, Caribbean, Fiji, Malaysia). The program has standardised practice and halved pertioneal dialysis-related infection. Implementation of multi-pronged strategies, now emulated by Canada and USA, led to establishment of a peritonitis registry, a national quality improvement program and publication of >50 papers on peritonitis, which influenced international PD guidelines. Highly cited and adopted internationally, the International Society for Pertioneal Dialysis (ISPD Guidelines) are considered the gold standard by other kidney care guideline groups. Finally, significant knowledge has been generated through the internationally endorsed Stanardised Outcomes in NephroloGy (SONG) initiative which uses shared priorities of patients, carers and clinicians to identify core outcome measures for kidney research. The ultimate result of the research program will be patient-prioritised research questions with outputs of critical importance to the global kidney care community that will inform international guidelines and policy, build capacity for international research collaboration and leadership, facilitate kidney care quality monitoring and reporting, and improve health outcomes for people with chronic kidney disease.
Works
Search Professor David Johnson’s works on UQ eSpace
2007
Conference Publication
Collapsing glomerulopathy secondary to human parvovirus b19 in a kidney-pancreas transplant recipient
Kaisar, M. O., Hawley, C. M., Mudge, D. W., Campbell, S. B., Johnson, D. W. and Isbel, N. M. (2007). Collapsing glomerulopathy secondary to human parvovirus b19 in a kidney-pancreas transplant recipient. 43rd Australian and New Zealand Society of Nephrology Annual Scientific Meeting, Gold Coast, Australia, 8–12 September 2007. Hoboken, NJ United States: Wiley-Blackwell.
2007
Journal Article
Central obesity is common in renal transplant recipients and is associated with increased prevalence of cardiovascular risk factors
Orazio, Linda, Armstrong, Kirsty, Banks, Merrilyn, Johnson, David, Isbel, Nikky and Hickman, Ingrid (2007). Central obesity is common in renal transplant recipients and is associated with increased prevalence of cardiovascular risk factors. Nutrition & Dietetics, 64 (3), 200-206. doi: 10.1111/j.1747-0080.2007.00151.x
2007
Journal Article
Evaluation of renal function: CARI guidelines
Johnson, David W. (2007). Evaluation of renal function: CARI guidelines. Australian Family Physician, 36 (1-2), 46-46.
2007
Conference Publication
Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients
Hourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. American Transplant Congress, San Francisco, CA, USA, 5-9 May 2007. Oxford, England: Wiley-Blackwell. doi: 10.1111/j.1600-6143.2007.01811.x
2007
Book Chapter
Hypokalaemia and Metabolic Alkalosis
Johnson, David W. (2007). Hypokalaemia and Metabolic Alkalosis. Clinical Cases in Kidney Disease. (pp. 1-1) edited by D.C.H. Harris. North Ryde, NSW Australia: McGraw-Hill Australia.
2007
Conference Publication
MSC protect renal tubular epithelium from oxidative stress in vitro: support for a protective or regenerative role in acute renal failure
Liu, H., McTaggart S., Johnson, D. W. and Gobe, G. C. (2007). MSC protect renal tubular epithelium from oxidative stress in vitro: support for a protective or regenerative role in acute renal failure. World Congress of Nephrology 2007 (WCN2007), Rio de Janeiro, Brazil, 21-25 April 2007. International Society of Nephrology.
2007
Conference Publication
Access infection in dialysis patients: A comparison of peritoneal vs haemodialysis in a large dialysis population
Clark, C. J., Johnson, D., Hawley, C., May, K., Campbell, S., Isbel, N., Mudge, D. and Burke, J. (2007). Access infection in dialysis patients: A comparison of peritoneal vs haemodialysis in a large dialysis population. 43rd Australian and New Zealand Society of Nephrology Annual Scientific Meeting, Gold Coast, Australia, 8–12 September 2007. Hoboken, NJ United States: Wiley-Blackwell Publishing.
2007
Conference Publication
Mycophenolic acid AUC on day 5 post-renal transplant and related outcomes in the early post-operative period
Staatz, Christine, Wong, Jenny, Taylor, Paul, Johnson, David and Tett, Susan (2007). Mycophenolic acid AUC on day 5 post-renal transplant and related outcomes in the early post-operative period. 10th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Nice, France, 9-14 September, 2007. New York: Lippincott-Raven. doi: 10.1097/FTD.0b013e31813797e8
2007
Journal Article
Modification of cardiovascular risk in hemodialysis patients: an evidence-based review
Johnson, David W., Craven, Ann-Maree and Isbel, Nicole Maree (2007). Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodialysis International, 11 (1), 1-14. doi: 10.1111/j.1542-4758.2007.00146.x
2007
Conference Publication
Vascular and structural cell response to erythropoietin in the neonatal brain during hypoxic injury
Yamada, M., Burke, C., Colditz, P., Johnson, D. W. and Gobe, G. C. (2007). Vascular and structural cell response to erythropoietin in the neonatal brain during hypoxic injury. Australian Society of Medical Research Annual Scientific Meeting, Blue Mountains, NSW, November, 2007.
2007
Conference Publication
Follow-up of 15 years of live donors in a large Australian renal transplant unit
Kaisar, M. O., Isbel, N., Hawley, C., Johnson, D., Mudge, D., Griffin, A., Wall, D., Preston, J., Nicol, D. and Campbell, S. (2007). Follow-up of 15 years of live donors in a large Australian renal transplant unit. 43rd Australian and New Zealand Society of Nephrology Annual Scientific Meeting, Gold Coast, Australia, 8–12 September 2007. Hoboken, NJ United States: Wiley-Blackwell.
2007
Conference Publication
TRAFs, CARDs and CIDEs are novel apoptotic gene families in therapy-treated renal cell carcinoma and potential diagnostic markers
Rajandram, R., Pat, B. K., Li, J., Percy, C. J., Johnson, D. W. and Gobe, G. C. (2007). TRAFs, CARDs and CIDEs are novel apoptotic gene families in therapy-treated renal cell carcinoma and potential diagnostic markers. National Cancer Research Institute Conference, Birmingham, England, 2-5 October, 2007.
2007
Journal Article
Administration of erythropoietin and its derivatives in renal disease: advantages, mechanisms and concerns
Gobe, Glenda C., Endre, Zoltan H. and Johnson, David W. (2007). Administration of erythropoietin and its derivatives in renal disease: advantages, mechanisms and concerns. Drug Discovery Today: Therapeutic Strategies, 4 (1), 79-84. doi: 10.1016/j.ddstr.2007.07.001
2007
Conference Publication
Peritonitis in Australian peritoneal dialysis patients: Microbiology, treatment and outcomes
Ghali, J., McDonald, S., Bannister, K. M., ANZDATA Peritonitis Working Group and Johnson, D. W. (2007). Peritonitis in Australian peritoneal dialysis patients: Microbiology, treatment and outcomes. Nephrology 2007: 43rd Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Gold Coast, QLD, Australia, 8-12 September 2007. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2007.00847.x
2007
Conference Publication
Molecular and cellular changes associated with age-related chronic kidney disease
Percy, C., Brown, L., Power, D., Johnson, D. W. and Gobe, G. C. (2007). Molecular and cellular changes associated with age-related chronic kidney disease. International Society of Nephrology's World Congress of Nephrology 2007, Rio de Janeiro, Brazil, 21-25 April 2007.
2007
Conference Publication
Hospital admission rates in alternate nightly nocturnal home haemodialysis
Van Eps, C. L., Jeffries, J. K., Ng, T. G., Isbel, N. M., Johnson, D. W., Campbell, S. B., Mudge, D. W. and Hawley, C. M. (2007). Hospital admission rates in alternate nightly nocturnal home haemodialysis. 43rd Australian and New Zealand Society of Nephrology Annual Scientific Meeting, Gold Coast, Australia, 8–12 September 2007. Hoboken, NJ United States: Wiley-Blackwell.
2007
Conference Publication
The effect of recombinant human erythropoietin (rhEPO) in renal cell carcinoma (RCC) chemotherapy
Li, J., Vesey, D. A., Johnson, D. W. and Gobe, G. C. (2007). The effect of recombinant human erythropoietin (rhEPO) in renal cell carcinoma (RCC) chemotherapy. World Congress of Nephrology, Rio De Janeiro, Brazil, 21-25 April , 2007. International Society of Nephrology (ISN).
2007
Conference Publication
Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients
Hourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Ghandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients. American Transplant Congress 2007, USA, 5-9 May 2007. UK: Wiley-Blackwell Publising Ltd.. doi: 10.1111/j.1600-6143.2007.01811.x
2007
Conference Publication
The effect of diabetes mellitus on access related infection in both peritoneal dialysis and haemodialysis patients
Clark, C. J., Johnson, D., Hawley, C., May, K., Campbell, S., Isbel, N., Mudge, D. and Burke, J. (2007). The effect of diabetes mellitus on access related infection in both peritoneal dialysis and haemodialysis patients. 43rd Australian and New Zealand Society of Nephrology Annual Scientific Meeting, Gold Coast, Australia, 8–12 September 2007. Hoboken, NJ United States: Wiley-Blackwell.
2007
Journal Article
Predictors of renal recovery in Australian and New Zealand end-stage renal failure patients treated with periotoneal dialysis
Craven, Ann-Maree S., Hawley, Carmel M., McDonald, Stephen P., Rosman, Johan B., Brown, Fiona G. and Johnson, David W. (2007). Predictors of renal recovery in Australian and New Zealand end-stage renal failure patients treated with periotoneal dialysis. Peritoneal Dialysis International, 27 (2), 184-191. doi: 10.1177/089686080702700216
Funding
Current funding
Past funding
Supervision
Availability
- Professor David Johnson is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Evaluating the risk factors of poor health and equity of healthcare access in children living with chronic kidney disease
Principal Advisor
-
Doctor Philosophy
Improving outcomes for people treated with peritoneal dialysis
Principal Advisor
Other advisors: Associate Professor Yeoung Jee Cho
-
Doctor Philosophy
Novel Approaches to Cardiovascular Risk Stratification in Chronic Kidney Disease
Principal Advisor
Other advisors: Associate Professor Yeoung Jee Cho
-
Doctor Philosophy
Patient-centred strategies to improve life goal attainment in people with kidney disease
Associate Advisor
Other advisors: Associate Professor Yeoung Jee Cho
-
Doctor Philosophy
Predictors of and interventions to improve uptake and technique survival and reduce burden of home dialysis treatment
Associate Advisor
Other advisors: Associate Professor Yeoung Jee Cho
-
Doctor Philosophy
Perioperative outcomes and risk assessment of patients on chronic kidney replacement therapy
Associate Advisor
Other advisors: Professor Carmel Hawley
-
Doctor Philosophy
Increemental dialysis to improve health outcomes in people starting haemodialysis
Associate Advisor
Other advisors: Professor Carmel Hawley, Associate Professor Andrea Viecelli
-
Master Philosophy
Standardised Reporting of Cardiovascular Outcomes in Kidney Transplant Recipients
Associate Advisor
Other advisors: Professor Carmel Hawley, Associate Professor Andrea Viecelli
-
-
Doctor Philosophy
Viral Complications Following Kidney Transplantationn
Associate Advisor
Other advisors: Associate Professor Nikky Isbel, Professor Carmel Hawley, Associate Professor Andrea Viecelli
Completed supervision
-
2025
Doctor Philosophy
Epidemiology, Treatment and Outcomes of Focal Segmental Glomerulosclerosis and Membranous Nephropathy
Principal Advisor
-
2022
Doctor Philosophy
Strategies to improve infectious complications in kidney transplant patients
Principal Advisor
Other advisors: Professor Carmel Hawley, Associate Professor Ross Francis
-
2016
Doctor Philosophy
Therapeutic interventions to improve clinical outcomes in advanced chronic kidney disease
Principal Advisor
Other advisors: Professor Carmel Hawley
-
2015
Doctor Philosophy
Inflammation in Peritoneal Dialysis: Investigating the Roles of Biocompatible Solutions and Biological Markers
Principal Advisor
Other advisors: Professor Carmel Hawley, Professor David Mudge
-
2005
Doctor Philosophy
IGF FAMILY MEMBERS IN RENAL CELL CARCINOMA: THEIR ROLES IN MALIGNANCIES AND THERAPEUTIC INTERVENTIONS
Principal Advisor
-
2019
Doctor Philosophy
Strategies to Improve Vascular Access Outcomes in Haemodialysis Patients
Joint Principal Advisor
Other advisors: Professor Carmel Hawley
-
2025
Doctor Philosophy
Establishing the Role of Metformin for ADPKD Through Therapeutic Investigation and Guideline Development
Associate Advisor
Other advisors: Dr Christine Staatz, Professor Carmel Hawley, Associate Professor Andrea Viecelli, Dr Andrew Mallett
-
2024
Doctor Philosophy
Improving Kidney Disease Detection and Risk Prediction Across Diverse Regional and Socioeconomic Settings
Associate Advisor
Other advisors: Associate Professor Sally Shrapnel
-
2022
Doctor Philosophy
Nutrition supplementation and gut health in chronic kidney disease
Associate Advisor
Other advisors: Dr Katrina Campbell
-
2020
Doctor Philosophy
The role of the adipose tissue microenvironment in kidney cancer
Associate Advisor
Other advisors: Associate Professor David Vesey, Dr Sumaira Hasnain
-
2019
Master Philosophy
Very early acute rejection in an Australian and New Zealand kidney transplant population
Associate Advisor
Other advisors: Professor Carmel Hawley, Associate Professor Yeoung Jee Cho, Associate Professor Ross Francis, Professor David Mudge
-
2016
Doctor Philosophy
Cardiac Biomarkers for The Diagnosis and Monitoring of Cardiovascular Disease in The Dialysis Population
Associate Advisor
Other advisors: Professor Carmel Hawley
-
2015
Doctor Philosophy
IDENTIFICATION OF POTENTIAL MEDIATORS OF OXIDATIVE DAMAGE AND TARGETS FOR NOVEL TREATMENTS FOR CHRONIC KIDNEY DISEASE
Associate Advisor
Other advisors: Professor Jeff Coombes
-
2015
Doctor Philosophy
Uraemic toxins & Synbiotics: A novel therapy for Chronic Kidney Disease
Associate Advisor
Other advisors: Dr Katrina Campbell
-
2013
Doctor Philosophy
Mechanisms of Cytoprotection by Erythropoietin (EPO) in the Hypoxia/Ischaemia-Injured Neonatal Brain
Associate Advisor
-
2010
Doctor Philosophy
Androgen receptor, caveolin-1 and androgen self-sufficiency in prostate cancer
Associate Advisor
Other advisors: Honorary Professor John Hooper
-
2009
Doctor Philosophy
Targeting genes for identification and treatment of renal cell carcinoma
Associate Advisor
Other advisors: Associate Professor David Vesey
-
2008
Doctor Philosophy
Targeting the myofibroblast to limit renal fibrosis: a model using cancer therapies
Associate Advisor
-
2004
Doctor Philosophy
MOLECULAR MECHANISM FOR RENAL FIBROSIS: ROLE OF THE MAPK FAMILY
Associate Advisor
-
Doctor Philosophy
Genetic Diagnostics in Genetic Renal Disease: Methods, Applications and Therapeutics
Associate Advisor
Media
Enquiries
For media enquiries about Professor David Johnson's areas of expertise, story ideas and help finding experts, contact our Media team: